Amgen Inc (AMGN) Received its Third Buy in a Row


After Mizuho Securities and Morgan Stanley gave Amgen Inc (NASDAQ: AMGN) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Yaron Werber maintained a Buy rating on Amgen Inc today and set a price target of $229. The company’s shares opened today at $175.89.

According to TipRanks.com, Werber is a 4-star analyst with an average return of 12.0% and a 62.5% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Prevail Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen Inc with a $204.82 average price target, representing a 16.4% upside. In a report issued on July 15, Morgan Stanley also maintained a Buy rating on the stock with a $207 price target.

See today’s analyst top recommended stocks >>

Amgen Inc’s market cap is currently $109.6B and has a P/E ratio of 14.23. The company has a Price to Book ratio of 10.12.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts